Home › Funds › Bellevue Group AG › SMMT
Bellevue Group AG position in SMMT
SUMMIT THERAPEUTICS INC · Health Care
Bellevue Group AG reported holding 2,113,681 shares of SMMT (SUMMIT THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$35.7M, representing 0.74% of its reported portfolio and ranking #35 among its reported holdings. Bellevue Group AG has disclosed SMMT holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Bellevue Group AG's SMMT position evolved
Bellevue Group AG first disclosed a stake in SMMT in Q3 2024 at 10,000 shares (US$219K). The position peaked in Q3 2026 at 2,113,681 shares, worth US$35.7M. Across 9 filings, Bellevue Group AG increased the stake 3 time(s), trimmed it 5 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 2,113,681 shares valued at US$35.7M — an increase of 2,098,402 shares quarter over quarter.. Notable position changes include a 1606% increase in Q4 2024 (shares rose 8% over the following quarter), a 60% trim in Q1 2025 (shares rose 10% over the following quarter), a 13734% increase in Q3 2026 (shares fell 30% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2024 | 10.00K | $219.00K | New |
| Q4 2024 | 170.59K | $3.04M | Add |
| Q1 2025 | 67.69K | $1.31M | Reduce |
| Q2 2025 | 41.74K | $888.18K | Reduce |
| Q3 2025 | 18.98K | $392.17K | Reduce |
| Q4 2025 | 14.26K | $249.44K | Reduce |
| Q1 2026 | 15.86K | $300.67K | Add |
| Q2 2026 | 15.28K | $222.62K | Reduce |
| Q3 2026 | 2.11M | $35.74M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SMMT and 13F data
SMMT (SUMMIT THERAPEUTICS INC) is a Health Care company. 47 other funds we track also report a position in SMMT — the largest reported positions include BAKER BROS. ADVISORS LP (US$554.4M), Kynam Capital Management, LP (US$50.7M), Affinity Asset Advisors, LLC (US$28.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SMMT
- BAKER BROS. ADVISORS LP 32.79M sh · $554.42M · Q3 2026
- Kynam Capital Management, LP 3.00M sh · $50.73M · Q3 2026
- Affinity Asset Advisors, LLC 1.70M sh · $28.75M · Q3 2026
- Logos Global Management LP 1.00M sh · $16.91M · Q3 2026
- GMT CAPITAL CORP 760.80K sh · $12.87M · Q3 2026
- Rock Springs Capital Management LP 715.00K sh · $12.09M · Q3 2026
- Ikarian Capital, LLC 650.00K sh · $10.99M · Q3 2026
- Eversept Partners, LP 526.65K sh · $8.91M · Q3 2026
- Simplify Asset Management Inc. 510.11K sh · $8.63M · Q3 2026
- First Turn Management, LLC 501.72K sh · $8.48M · Q3 2026
- Elmind Capital, LP 493.82K sh · $8.35M · Q3 2026
- HOHIMER WEALTH MANAGEMENT, LLC 441.65K sh · $7.47M · Q3 2026
More on Bellevue Group AG
FAQ
How long has Bellevue Group AG held SMMT?
Bellevue Group AG has disclosed SMMT holdings in 9 of the last 9 reported quarters, going back to Q3 2024.
What is Bellevue Group AG's current position in SMMT?
As of Q3 2026, Bellevue Group AG holds 2.11M shares of SMMT (SUMMIT THERAPEUTICS INC), valued at $35.74M, representing 0.74% of its reported portfolio and ranking #35.
Has Bellevue Group AG been buying or selling SMMT?
In the latest 13F filing (Q3 2026), Bellevue Group AG increased its position in SMMT. The position peaked in Q3 2026 at 2.11M shares.
Which other funds hold SMMT?
Other major institutional holders of SMMT include BAKER BROS. ADVISORS LP, Kynam Capital Management, LP, Affinity Asset Advisors, LLC, among 47 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.